Product Images Fulvestrant

This appears to be a graph showing the progression-free survival rate of two doses of Fulvestrant (250mg and 500mg) over a period of 45 months. The x-axis represents the time in months and the y-axis represents the number of patients who remained free from disease progression. The number of patients at risk for each dose is listed at each time point.*

The provided text contains a graph showing over time the number of patients still alive while receiving different doses of a drug called Fulvestrant. The graph shows that patients who received the 500mg dose had a lower survival rate over time compared to patients receiving the lower 250mg dose. The last statement suggests that the data may not be statistically significant without adjustments.*

This is a graph depicting the progression-free survival of two treatments for breast cancer: Palbociclib+fulvestrant versus placebo+fulvestrant. Palbociclib+fulvestrant shows greater efficacy in reducing cancer progression as compared to placebo+fulvestrant. The graph also shows the number of patients at risk for each treatment over the course of time.*

This is a chart that compares two treatment options for an unspecified medical condition. These options are fulvestrant with a placebo and a combination of fulvestrant and palbociclib. The chart shows the overall survival probability in percentage for patients over a period of 54 months. The number of patients at risk for the two options is also indicated at different time points.*

Not available.*

This is a description of Fulvestrant Injection, which is for single-dose intramuscular use only. It comes in a carton that contains two pre-filled syringes each containing 250 mg per 5 mL (50 mg per mL) and two SafetyGlide™ shielding intramuscular injection needles. Both syringes must be administered to receive the 500 mg dose. It can be stored at controlled room temperature or refrigerated conditions, but should not be frozen. It is important to protect from light, and store in the original carton until use. The manufacturer is Fresenius Kabi and it is available via prescription only.*

This is a description of a medication called Fulvestrant. It comes in an injection form, with a strength of 250mg per 5mL (50mg per mL). It is intended for intramuscular use only and should be administered using a bath syringe. A single-dose syringe with a code of 63323-715-01 is also available. This medication should only be prescribed by a doctor. Other details include a manufacturer address in Lake Zurich, IL and a reference to a code MOG1225/00 US 403319.*